European bioregions : strengths and partnership strategies. The bioxclusters example BioPartnering Latin America cluster forum september 2013

Size: px
Start display at page:

Download "European bioregions : strengths and partnership strategies. The bioxclusters example BioPartnering Latin America cluster forum september 2013"

Transcription

1 European bioregions : strengths and partnership strategies. The bioxclusters example BioPartnering Latin America cluster forum september 2013

2 Contents Who we are Our goals Our activities Wha we can offer What we will represent in the future 23 April,

3 Why to cooperate? mutual learning exchange of good practice joint business opportunities development of common strategies exchange of qualified staff mobility of firms sharing incubation facilities mutually sharing access to networks and international partnerships access to international markets and business development in new market mutually exchange technical competences share research infrastructure and production facilities economies of scale

4 bioxclusters Regional clusters partnership 4

5 Who are we? bioxclusters is a European initiative, funded by the European Commission, uniting 4 regions in Europe with one single approach: Supporting the competitiveness of European clusters SMEs by facilitating internationalisation and access to global markets 5

6 Our assets MAIN SECTORS THERAPEUTIC AREAS TECHNOLOGY SPECIALITIES Biotechnology Oncology Health care Cardiovascular Biomedicine Infectious diseases Regenerative Med. Inflamatory diseases Biopharmaceutical Neurological diseases Diagnostics Autoimmune diseases Personalised Medicine Nanomedicine Targeted therapies Drug Development Medical technologies Diagnostics Solutions 6

7 Four European partners 7

8 Catalonia (Spain) with capital in Barcelona 1997 Barcelona Science Park was created 2006 Creation of Biocat Private Foundation Promotes and develops life sciences in Catalonia 2013 Launch of the First Edition of Design Health Barcelona program The Bioregion of Catalonia Main biotech hub in Spain 480 companies 435 Research Groups 10 Universities 3 Large-scale R&D Infrastructures 15 university hospitals 20 Science parks Visit us in Follow us on twitter (@biocat.en) and Linkedin Main Therapeutic Areas Oncology Neurosciences Cardiovascular Dermatology Technological Strengths Nanobiomedicine Genomics & Structural Biology Drug Design Bioinformatics Fostering talent d HEALTH Barcelona Organization of BIoEurope Spring 2010 & 2013 INTERNATIONALIZATION/GLOBALIZATION: Facilitating access to markets through: Network of local contacts in foreign markets Agreements with science parks and other organizations Main Interests: USA Asia (China, Japan & India) South America Member of CEBR Council of European Bioregions & EDCA

9 Germany Foundation of first biotech SME Establishment of Bio M cluster organisation 338 biotech & pharma companies: 178 biotech SMEs 37 biotech non-smes 37 pharma companies 86 CROs & suppliers Bavaria (Germany) and Greater Munich 2010 Start of Munich Initiative for Personalized Medicine ( employees in total, in biotech SMEs Bio M Biotech Cluster Development GmbH Personalised Medicine & Targeted Therapies, Therapeutics & Diagnostics, Devices, Analytics, Informatics m4 Initiative for Personalized Medicine & Targeted Therapies : INTERNATIONALIZATION / GLOBALIZATION: Growth through partnerships and collaborations in Europe and worldwide. Oncology, Cardiovascular diseases Autoimmune diseases Close collaboration with regional medtech network 100 mio for 5 years, 35 R&D projects, 5 infrastructure projects, m4 Award for start-ups, collaborations between SMEs and academia / hospitals. Main interest of members: Asia (China & Japan) and USA Member of CEBR Council of European Bioregions

10 Piemonte region (Italy) Main city Torino (Turin) Personalised health care/converging technologies Innovative biomedical devices (Prosthesis) Imaging Regenerative medicine Oncology, CNS, Autoimmune diseases Start-up creation Science park creation 2009-Cluster initiative inception ALISEI Member Bioeurope Spring 2014 in Torino 30 R&D projects launched involving 70 actors in the last 4 years 400-in total 270 health care employees SME No: 95% 27 MNC 3900 scientist in R&D institutions biopmed health care cluster Bioindustry Park Silvano Fumero SpA Science park INTERNATIONALIZATION/GLOBALIZATION: Growth through partnerships and collaborations 14+ MOU with international actors 147 SMEs supported (last 4 years) 10+ international projects ongoing and realized CEBR Council of European Bioregions 2 Multinational corporations as shareholder of the science park Metaclustering approach to have critical mass based on complementarities

11 Rhone-Alpes Region (France) Main cities Lyon & Grenoble >2005 Establishment of the French cluster policy and creation of Lyonbiopole >2012 EU Bronze Label Awarded and Lyonbiopole assessed as the most performing French BioCluster companies in health care employees scientists >4 World Class leaders: biomérieux, Sanofi, BD, Merial. >8 International R&D Infrastructures >130 official members > 134 R&D projects = total of 667 million LYONBIOPOLE Rhone-Alpes BioCluster Infectious diseases Immune Disorders Cancers Personalized medicine Biotherapies & Vaccines Diagnostics Delivery systems Devices Close collaboration with regional medtech network sq.m of biomanufacturing & bioanalysis labs 1 920sq.m of BSL 2/3 Labs Technological Research Institute on Infectious Diseases & Microbiology European Network on System Biology & Medicine INTERNATIONALIZATION/GLOBALIZATION: >Internationalization based on a dual approach: interclustering and support to SMEs. >3 main target markets: North America (USA + Canada), Brazil & China >One representative based in Shanghai >Member of CEBR Council of European Bioregions & EDCA >In 2012: + 50 companies supported & 6 international trade missions

12 Our goals and activities 12

13 3 target markets Brazil China US With 2 main objectives Supporting European SMEs internationalisation and creating a single European entry point for global biotech & health players 13

14 Main activities and achievements up to now Brazil China Hosting Eduardo Soares, CEO of Biominas (Minas Gerais), in Europe (April 2012) 1 country report (Sept 2012) Mission to Sao Paulo & Rio de Janeiro (Sept 2012) Institut Butantan, CIETEC, FAPESP, FioCruz, BIORIO, Recepta, Pitanga, FINEP Participation in BioPartnering Latin America 2012 Signature of an MoU for 2 years with Health Foundation and Technological Park of Ribeirão Preto region, Brazil (March 25, 2013) Signature with MOU with Biorio (September 2013) Mission with European Commission (Sept 2013). Participation in BioPartnering Latin America 2013 Hosting Gao Ronghui, CEO of G-med Consulting (Shanghai), in Europe (Jan 2013) 1 country report (Jan 2013) Mission to Shanghai region, with around 15 EU companies from 4 countries (): Co-organisation of a Sino-European Partnering Day Participation in BioForum conference and visits (parks, hospitals, companies) Signatures of MoUs with Zhangjiang Park + Juke Biotech Park US Hosting Karin Hollerbach, CEO Taku Group (Silicon Valley) in Europe (April 2013) 1 country report in progress (September 2013) Mission with EU companies planned (October 2013) 14

15 What can we offer? 15

16 What can we offer? bioxclusters, a unique metacluster, your entry point to access the European healthcare market Expertise on European biotech and medtech market opportunities and regulations Access to high quality innovative players (SMEs & academic research partners) Collaboration potential in many innovative R&D and drug development projects High-tech solutions for the Chinese healthcare market Activities are realised in complementarity 16

17 Building win-win exchanges Providing European market key data and knowing better foreign markets Supporting European SMEs to reach target markets, create new technological and commercial reciprocal opportunities Identifying new partners between respective countries players (companies, academics, clusters) Building long-term relations between European clusters and foreign counterparts 17

18 bioxclusters contact details Mamen Marti Dr. Daniela Tonn Fabrizio Conicella Emilie Romeo Elisabetta Schena Head of Internationalisation (Business Development) International Affairs & Training Director Business Development and Internation Projects park.it Project manager e.com International Cluster Development Project Manager +34 (0) (0) (0) (0) (0)

19 Thank you for your attention Visit us at Follow us on Twitter and Linkedin Partners: Coordinated by:

Alps Bio Cluster Biotech and medtech in Alpine Space

Alps Bio Cluster Biotech and medtech in Alpine Space VIIth European Mountain Conference, 15th-17th September 2010, Lillehammer, Norway Alps Bio Cluster Biotech and medtech in Alpine Space www.alpsbiocluster.eu Alpine Space programme European territorial

More information

TECHNOLOGICAL RESEARCH INSTITUTE FOR A COMPREHENSIVE AND PERSONALIZED MANAGEMENT OF INFECTIOUS DISEASES

TECHNOLOGICAL RESEARCH INSTITUTE FOR A COMPREHENSIVE AND PERSONALIZED MANAGEMENT OF INFECTIOUS DISEASES TECHNOLOGICAL RESEARCH INSTITUTE FOR A COMPREHENSIVE AND PERSONALIZED MANAGEMENT OF INFECTIOUS DISEASES Tackle public health challenges linked to infectious diseases RESPONSIBLE FOR 14 million deaths each

More information

Bavarian Biotech Inside Shaping the Future of Medicine.

Bavarian Biotech Inside Shaping the Future of Medicine. Bavarian Biotech Inside Shaping the Future of Medicine Bio M accelerating biomedical innovation Vision Bavaria the place for the medicine of the future Mission Bio M recognizes the challenges of the medicine

More information

Investments in the Life Sciences

Investments in the Life Sciences Investments in the Life Sciences where how why June 4 th, 2014 Horst Domdey History of the Munich Biotech Cluster 1984 Foundation of the Munich Gene Center 1989 1 st Munich biotech company 1996 Munich

More information

Welcome to 5 th Munich Biomarker Conference

Welcome to 5 th Munich Biomarker Conference Clinical Practice and Targeted Therapies in Personalized Medicine Welcome to 5 th Munich Biomarker Conference December 1 st 2 nd, 2015 RAMADA Hotel & Conference Center München Messe We thank our sponsors

More information

Alps Bio Cluster Biotech and Medtech in the Alpine Space ( )

Alps Bio Cluster Biotech and Medtech in the Alpine Space ( ) Alps Bio Cluster Biotech and Medtech in the Alpine Space (2008 2011) www.alpsbiocluster.eu Alpine Space programme European territorial cooperation 2007 2013 Peter Schröder, Helmholtz-Zentrum München, FRG

More information

Wednesday October 14, Invitation only. For more information, please visit

Wednesday October 14, Invitation only. For more information, please visit Wednesday October 14, 2015 Startup Acceleration Training (8:00-15:00) Sponsored by: 08:00-15:00 Invitation only. For more information, please visit http://goo.gl/forms/fpm0vdyciz. Biocluster Workshop -

More information

Wednesday October 14, Invitation only. For more information, please visit

Wednesday October 14, Invitation only. For more information, please visit Wednesday October 14, 2015 Startup Acceleration Training (8:00-15:00) 08:00-15:00 Invitation only. For more information, please visit http://goo.gl/forms/fpm0vdyciz. Biocluster Workshop - Internationalization

More information

What is One Nucleus? Vision. Mission

What is One Nucleus? Vision. Mission One Nucleus What is One Nucleus? A membership organisation Funded by sponsorship, membership fees, events and projects Based in Cambridge and London but with global members Formed by merger of ERBI and

More information

Interna'onalisa'on strategies and med tech companies. Fabrizio Conicella

Interna'onalisa'on strategies and med tech companies. Fabrizio Conicella Interna'onalisa'on strategies and med tech companies Fabrizio Conicella conicella@bioindustrypark.it - Globalisa9on and interna9onal expansion - Interna9onaliza9on and med tech: from theory to prac9ce

More information

BIOTECH IN FRANCE. key info in. points

BIOTECH IN FRANCE. key info in. points BIOTECH IN FRANCE 10 key info in points 1 2 3 INSERM: EUROPE S #1 ACADEMIC BIOTECH RESEARCH INSTITUTE INSERM spearheads healthcare and medical research in France, filing more biotech patents with the European

More information

Develop YOUR business in Medicon Valley Dedicated to helping you develop your business, Medicon Valley offers:

Develop YOUR business in Medicon Valley Dedicated to helping you develop your business, Medicon Valley offers: MEDICON VALLEY / 2011 03 Develop YOUR business in Medicon Valley Dedicated to helping you develop your business, Medicon Valley offers: > A pool of highly qualified life-science university graduates and

More information

Policies that encourage innovation in middle-income countries

Policies that encourage innovation in middle-income countries December 2012 Policies that encourage innovation in middle-income countries The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) asked Charles River Associates (CRA) to

More information

Università Cattolica del Sacro Cuore

Università Cattolica del Sacro Cuore Università Cattolica del Sacro Cuore The role of Regulatory Affairs in drug development Francesco Mazza, Director of Legal, Fiscal & Compliance Affairs in Farmindustria Rome, May 12 2017 Who we are Who

More information

EU Initiative Fostering SME Internationalization Through Clusters

EU Initiative Fostering SME Internationalization Through Clusters EU Initiative Fostering SME Internationalization Through Clusters European Contract N SI2.612891 3/G/ENT/CIP/11/C/N04C011 TABLE OF CONTENTS 1. Introduction 1.1 The country 1.2 Chinese market overview 1.3

More information

The Belgian pharmaceutical industry strengthens its leading European position. Belgian pharma figures 2015, in a European perspective

The Belgian pharmaceutical industry strengthens its leading European position. Belgian pharma figures 2015, in a European perspective The Belgian pharmaceutical industry strengthens its leading European position Belgian pharma figures 2015, in a European perspective INTRODUCTION In 2015, Belgium continued to reinforce its leading position

More information

Inaugural Fraunhofer Delaware Technology Summit

Inaugural Fraunhofer Delaware Technology Summit Inaugural Fraunhofer Delaware Technology Summit Energy and Life Sciences Solu

More information

The Innovative Medicines Initiative: Building new models of collaborative research across Europe

The Innovative Medicines Initiative: Building new models of collaborative research across Europe The Innovative Medicines Initiative: Building new models of collaborative research across Europe Elisabetta Vaudano IMI, Belgium www.imi.europa.eu What is IMI? An European Public-Private Partnership Focused

More information

Innovative Medicines Initiative

Innovative Medicines Initiative Innovative Medicines Initiative EMA - EBE Regulatory Conference on ATMPs Salah-Dine Chibout, Novartis Global Head Discovery & Investigative Safety/ Global Head Preclinical Safety Therapeutic Areas IMI

More information

TAIWAN. Who Should Attend? Endless Potential & Opportunities. Where innovations are shaping a new era of intelligent healthcare.

TAIWAN. Who Should Attend? Endless Potential & Opportunities. Where innovations are shaping a new era of intelligent healthcare. TAIWAN Where innovations are shaping a new era of intelligent healthcare World-class medical centers and hospitals Over 1800 biotech companies Best healthcare system in the world Top-ranked life science

More information

BioWorld s PARTNER in FOCUS: Open Innovations: Moscow

BioWorld s PARTNER in FOCUS: Open Innovations: Moscow BioWorld s PARTNER in FOCUS: Open Innovations: Moscow GLOBAL BIOPHARMA INDUSTRY SEES OPPORTUNITY IN RUSSIA Top executives from companies as diverse at Medtronic, Pfizer, EADS, Google, Sanofi Pasteur and

More information

NEWSFLASH 03. FASILIS update. FASILIS: Stimulating new business development in Human Health

NEWSFLASH 03. FASILIS update. FASILIS: Stimulating new business development in Human Health NEWSFLASH 03 FASILIS: Stimulating new business development in Human Health FASILIS (Facility Sharing in Life Sciences) is an international pilot project creating transnational links between SMEs and a

More information

News For Immediate Release

News For Immediate Release News For Immediate Release Contact: Gary Gatyas IMS Institute for Healthcare Informatics (610) 244-2600 ggatyas@us.imshealth.com IMS Study Forecasts Rebound in Global Spending on Medicines, Reaching Nearly

More information

EUROPEAN TECHNOLOGY PLATFORM NANOMEDICINE. Work plan for GA, 16th January 2008

EUROPEAN TECHNOLOGY PLATFORM NANOMEDICINE. Work plan for GA, 16th January 2008 Work plan for 2008 1 Vision In 10 years nanomedicinebased products will lead to breakthroughs in the treatment of diseases such as cardiovascular disease, cancer, CNS diseases and diabetes. 2 The ETP is

More information

THE FUTURE OF HEALTH IS BEING INVENTED IN NANTES SAINT-NAZAIRE

THE FUTURE OF HEALTH IS BEING INVENTED IN NANTES SAINT-NAZAIRE JOIN A RICH ECOSYSTEM Atlanpole Science a Technology Park, European Business & Innovation Center, Regional Incubator for the Pays de la Loire. Atlanpole Biothérapies Competitiveness cluster with 30 members

More information

We are the right partner for

We are the right partner for We are the right partner for all kind of transactions in the Pharma / Healthcare Industry Mergers & Acquisitions (share deals) Divestments and acquisitions of companies Specialization in divestment of

More information

BIOHEALTH INDUSTRY. Start Your Career in Wisconsin s BIOTECH AND BIOPHARMA MEDICAL DEVICE AND DIAGNOSTICS HEALTH RESEARCH INSTITUTES BIO- MANUFACTURE

BIOHEALTH INDUSTRY. Start Your Career in Wisconsin s BIOTECH AND BIOPHARMA MEDICAL DEVICE AND DIAGNOSTICS HEALTH RESEARCH INSTITUTES BIO- MANUFACTURE Start Your Career in Wisconsin s BIOHEALTH INDUSTRY BIOTECH AND BIOPHARMA MEDICAL DEVICE AND DIAGNOSTICS HEALTH RESEARCH INSTITUTES DIGITAL HEALTH BIO- MANUFACTURE Be Part of Wisconsin s BIOHEALTH INDUSTRY

More information

Swiss Medtech - Europe Medtech Development Dr. Patrik Frei September 2014 Suzhou

Swiss Medtech - Europe Medtech Development Dr. Patrik Frei September 2014 Suzhou Swiss Medtech - Europe Medtech Development Dr. Patrik Frei September 2014 Suzhou 1 Overview 1. Overview European Medtech Venture Valuation: Independent assessment and valuation of technology driven companies

More information

The Innovative Medicines Initiative Europe s partnership for health. Tek-Ang LIM, 20 June 2018, Brussels

The Innovative Medicines Initiative Europe s partnership for health. Tek-Ang LIM, 20 June 2018, Brussels The Innovative Medicines Initiative Europe s partnership for health Tek-Ang LIM, 20 June 2018, Brussels 10 YEARS OF LIGHTING THE WAY IMI Why Europe s partnership for health? Because despite decades of

More information

HIGH-TECH INDUSTRIES BIOTECH IN FRANCE KEY INFO IN POINTS

HIGH-TECH INDUSTRIES BIOTECH IN FRANCE KEY INFO IN POINTS HIGH-TECH INDUSTRIES BIOTECH IN FRANCE KEY INFO IN 10 POINTS 1 67 BILLION IN REVENUES The biotech-medtech industry accounted for around 330,000 direct and indirect jobs and 67 billion in sales in 2016

More information

Modern Slavery Statement

Modern Slavery Statement Modern Slavery Statement for the year ended 31 December 2017 Our commitment We run every part of our business with integrity, honesty, and transparency everywhere we operate. We do not allow modern slavery

More information

BIOHEALTH INDUSTRY. Start Your Career in Wisconsin s BIOTECH AND BIOPHARMA MEDICAL DEVICE AND DIAGNOSTICS HEALTH RESEARCH INSTITUTES BIO- MANUFACTURE

BIOHEALTH INDUSTRY. Start Your Career in Wisconsin s BIOTECH AND BIOPHARMA MEDICAL DEVICE AND DIAGNOSTICS HEALTH RESEARCH INSTITUTES BIO- MANUFACTURE Start Your Career in Wisconsin s BIOHEALTH INDUSTRY BIOTECH AND BIOPHARMA MEDICAL DEVICE AND DIAGNOSTICS HEALTH RESEARCH INSTITUTES DIGITAL HEALTH BIO- MANUFACTURE Be Part of Wisconsin s BIOHEALTH INDUSTRY

More information

MARKETS & CUSTOMERS. Progressing globalization. Evolving markets

MARKETS & CUSTOMERS. Progressing globalization. Evolving markets Peptides are used worldwide in medical research. They contribute immensely to the understanding of diseases and have proven to be effective in medicinal products. Today, peptides can be produced at low

More information

Facts&figures of the Pharmaceutical industry in Italy. July 2018

Facts&figures of the Pharmaceutical industry in Italy. July 2018 Facts&figures of the Pharmaceutical industry in Italy July 2018 Key figures of the Pharma sector in Italy Pharma industry in Italy by nationality of ownership (% on total) 40% Italian-owned companies 200

More information

KPI Definition Comment Relates to Baseline Target

KPI Definition Comment Relates to Baseline Target IMI2 Key performance indicators (KPIs) Reporting on measuring and outcomes on the ten following Key Performance Indicators will be provided yearly as part of the IMI2 JU Annual Activity Reports for year

More information

Fostering Convergent Scientific Research and Industry Engagement in a University Setting: Challenges and Strategies

Fostering Convergent Scientific Research and Industry Engagement in a University Setting: Challenges and Strategies Fostering Convergent Scientific Research and Industry Engagement in a University Setting: Challenges and Strategies Colin Duckett, Ph.D. Professor, Departments of Pathology & Internal Medicine Director,

More information

L A B O R M A R K E T B R I E F I N G S S E R I E S

L A B O R M A R K E T B R I E F I N G S S E R I E S L A B O R M A R K E T B R I E F I N G S S E R I E S LABOR MARKET INFORMATION FOR RESEARCHERS THE LIFE SCIENCE AND PHARMACEUTICALS SECTOR IN EUROPE L I F E S C I E N C E A N D P H A R M A C E U T I C A

More information

THE BIOREGION OF CATALONIA AT BIO-EUROPE SPRING 2013

THE BIOREGION OF CATALONIA AT BIO-EUROPE SPRING 2013 7th Annual International Partnering Conference THE BIOREGION OF CATALONIA AT BIO-EUROPE SPRING 2013 March 11-13, 2013 - CCIB Barcelona International Convention Center Plaça de Willy Brandt 11-14, Barcelona

More information

Collaborations between pharma industry and academia as drivers for innovations

Collaborations between pharma industry and academia as drivers for innovations Collaborations between pharma industry and academia as drivers for innovations Dr. Monika Lessl Director Alliance Management Global Drug Discovery Bayer Schering Pharma Berlin, Germany Deutsch - Brasilianische

More information

New Ways to Source Innovation in the Healthcare Industry In-licensing needs Oncology of Janssen/Johnson & Johnson Innovation

New Ways to Source Innovation in the Healthcare Industry In-licensing needs Oncology of Janssen/Johnson & Johnson Innovation New Ways to Source Innovation in the Healthcare Industry In-licensing needs Oncology of Janssen/Johnson & Johnson Innovation Dr. Klaus Suwelack Johnson & Johnson Innovation, Janssen-Cilag Germany, Neuss

More information

February 25, 2019 (Monday) 8:30-16:30 Hrs BioPark Visit (Only for Invitees)

February 25, 2019 (Monday) 8:30-16:30 Hrs BioPark Visit (Only for Invitees) February 25, 2019 (Monday) 8:30-16:30 Hrs BioPark Visit (Only for Invitees) 18:00-19:30 Hrs Inauguration of the 16 th BioAsia Convention Presentation of Genome Valley Excellence Award 19:30-20:00 Hrs Inauguration

More information

Santara Valley experience in new health technologies. Vladas Algirdas Bumelis

Santara Valley experience in new health technologies. Vladas Algirdas Bumelis Santara Valley experience in new health technologies Vladas Algirdas Bumelis 1 Santara Valley Integrated scientific and business center was established in 2008. It will be finished by the end of 2013.

More information

CONTRACT RESEARCH SERVICES

CONTRACT RESEARCH SERVICES 1537 NW 65th Avenue Plantation, FL 33313 USA Phone: (954) 321-8988 Fax: (954) 321-9778 info@receptopharm.com www.receptopharm.com ReceptoPharm has installed the pathways to develop, produce and supply

More information

To meet the challenge of providing safe, cost-effective medicines for the world s largest

To meet the challenge of providing safe, cost-effective medicines for the world s largest An Executive Summary Biopharma in China: New Initiatives, New Opportunities To meet the challenge of providing safe, cost-effective medicines for the world s largest population, the government of China

More information

RIEMSER Pharma GmbH Ready for the Future

RIEMSER Pharma GmbH Ready for the Future RIEMSER Pharma GmbH Ready for the Future Jefferies Health Care Conference 19 th & 20 th November 2014 The Waldorf Hilton, London 01.05.2011 Präsentationstitel von Dr. Vorname Nachname 1 Fast international

More information

THE NEW FRANCE. WHERE THE SMART MONEY GOES.

THE NEW FRANCE. WHERE THE SMART MONEY GOES. COMPETITIVENESS CLUSTERS IN FRANCE THE NEW FRANCE. WHERE THE SMART MONEY GOES. Where are they? What do they represent? On July 2005, the French government has decided to grant an official label and to

More information

STRATEGIC PLAN

STRATEGIC PLAN STRATEGIC PLAN 2014-2018 A LONG TERM VISION SERVING THE INNOVATION AND THE ECONOMIC DEVELOPMENT OF THE HEALTH INDUSTRY IN PARIS REGION 1 GOAL By the year 2020, the ambition of Medicen Paris Region is to

More information

Welcome to the Ministry of Foreign Affairs

Welcome to the Ministry of Foreign Affairs Welcome to the Ministry of Foreign Affairs indk@um.dk www.investindk.com National Experimental Therapy Partnership (NEXT) NEXT is a public-private partnership within clinical research offering a one stop

More information

Fare clic per modificare lo stile del sottotitolo dello schema THE BIOTECH SECTOR IN ITALY AND LOMBARDY

Fare clic per modificare lo stile del sottotitolo dello schema THE BIOTECH SECTOR IN ITALY AND LOMBARDY Fare clic per modificare lo stile del sottotitolo dello schema THE BIOTECH SECTOR IN ITALY AND TABLE OF CONTENT 1. THE BIOTECH SECTOR IN ITALY 2. : A LAND OF OPPORTUNITIES 3. : BIOTECH FACTS AND FIGURES

More information

RECEPTA biopharma. Early drug development in a start-up company. Jose Fernando Perez CEO

RECEPTA biopharma. Early drug development in a start-up company. Jose Fernando Perez CEO RECEPTA biopharma Early drug development in a start-up company Jose Fernando Perez CEO 1 The Challenges of a Biotech in Brazil Networking for cancer drug development Why in Brazil? 2 Brief History Fernando

More information

Keynote address for the first CIFAL-Shanghai Training Workshop on e-administration

Keynote address for the first CIFAL-Shanghai Training Workshop on e-administration Keynote address for the first CIFAL-Shanghai Training Workshop on e-administration Marcel A. Boisard UN Assistant Secretary General Executive Director of UNITAR 21 February 2005 Wan Ping Hotel, Shanghai,

More information

Joint Statement on the Innovative Medicines Initiative

Joint Statement on the Innovative Medicines Initiative Joint Statement on the Innovative Medicines Initiative FOR IMMEDIATE RELEASE Brussels, 6 July 2010 The Innovative Medicines Joint Technology Initiative (IMI) was launched in May 2007. From the beginning,

More information

Stem Cell Research: Identifying emerging high priority policy issues

Stem Cell Research: Identifying emerging high priority policy issues The state stem cell agency Stem Cell Research: Identifying emerging high priority policy issues Ellen G. Feigal, M.D. SVP, Research and Development National Cancer Policy Summit Washington, DC November

More information

Bioeconomy and Opportunities in the Bio-based Industry of Malaysia. Dr. Abdul Manaf Mohamad Radzi

Bioeconomy and Opportunities in the Bio-based Industry of Malaysia. Dr. Abdul Manaf Mohamad Radzi Bioeconomy and Opportunities in the Bio-based Industry of Malaysia Dr. Abdul Manaf Mohamad Radzi Malaysia s Strategic Advantages in Bioeconomy Government with strong interest in the Bioeconomy sector Abundance

More information

Universal Biosensors, Inc.

Universal Biosensors, Inc. Universal Biosensors, Inc. ARBN 121 559 993 UBS Australian Healthcare Conference November 2011 1 Important Disclaimer This presentation is intended to provide a general outline only and is not intended

More information

Pharmaceutical Product Development NASDAQ: PPDI. Dan Darazsdi Chief Financial Officer. Credit Suisse Healthcare Conference November 2009

Pharmaceutical Product Development NASDAQ: PPDI. Dan Darazsdi Chief Financial Officer. Credit Suisse Healthcare Conference November 2009 Pharmaceutical Product Development NASDAQ: PPDI Dan Darazsdi Chief Financial Officer Credit Suisse Healthcare Conference 2009 12 November 2009 Safe Harbor Except for historical information, all of the

More information

EU support for Health Research from FP6 to FP7

EU support for Health Research from FP6 to FP7 EU support for Health Research from FP6 to FP7 Stéphane Hogan Head of Biotechnology Unit Directorate for Health Research DG Research - European Commission Valencia - 15 September 2006 EU research programmes

More information

Nanotechnology and Advanced Materials for more effective Healthcare

Nanotechnology and Advanced Materials for more effective Healthcare Nanotechnology and Advanced Materials for more effective Healthcare This challenge taps into the potential of nanotechnologies and advanced materials to enable more effective therapies and diagnostics

More information

Biotech / Life Science Sector

Biotech / Life Science Sector Trends in the Canadian and UK Biotech / Life Science Sector Dr. Patrik Frei December 2012 London Venture Valuation Mission Independent assessment and valuation of technology driven companies / products

More information

7TH EPLS CONFERENCE PRAGUE, SEPTEMBER 23-24, 2014

7TH EPLS CONFERENCE PRAGUE, SEPTEMBER 23-24, 2014 7TH EPLS CONFERENCE PRAGUE, SEPTEMBER 23-24, 2014 PIERRE FABRE 2 2013 KEYS FIGURES PHARMACEUTICALS DERMO-COSMETICS TURNOVER TURNOVER: 910 M ; 45% TURNOVER: 1089 M ; 54% 2008 M 3 FOOTPRINT GLOBAL REACH

More information

IMMUNOASSAY MARKET. Global Forecast to MarketsandMarkets

IMMUNOASSAY MARKET. Global Forecast to MarketsandMarkets IMMUNOASSAY MARKET [Technology (Enzyme, Fluorescent, Chemiluminescence, Radioimmunoassay), Analyzers & Reagents, Application (Infectious Diseases, Cancer, Endocrinology, Cardiology), End-Users (Hospitals,

More information

A European Public-Private Partnership! in Healthcare! Michel Goldman, MD,PhD Executive Director

A European Public-Private Partnership! in Healthcare! Michel Goldman, MD,PhD Executive Director A European Public-Private Partnership! in Healthcare! Michel Goldman, MD,PhD Executive Director ITMAT 2010, 27 October 2010 EFPIA Member Companies Participating companies (September 2010):! Innovative

More information

Precision Medicine. Presented by:

Precision Medicine. Presented by: Precision Medicine Presented by: Prepared Brendan FitzGerald For: Enabling better health through information technology. Healthcare Information and Management Systems Society (HIMSS) HIMSS is a global,

More information

Working Together for Better Health Partnering with Boehringer Ingelheim. JOURNEE COLLABORATIVE DE LYONBIOPOLE October 10, 2017

Working Together for Better Health Partnering with Boehringer Ingelheim. JOURNEE COLLABORATIVE DE LYONBIOPOLE October 10, 2017 Working Together for Better Health Partnering with Boehringer Ingelheim JOURNEE COLLABORATIVE DE LYONBIOPOLE October 10, 2017 Welcome to Partnering with Boehringer Ingelheim Our guiding principle Value

More information

Partnering & Networks

Partnering & Networks Partnering & Networks Success drivers in an ever changing and complex health care system Dr. Benedikt Hoffmann, Senior Manger New Business Development & J&J Innovation Manager October 2 nd, 2014 Judith

More information

CALIFORNIA S BIOTECHNOLOGY WORKFORCE TRAINING NEEDS FOR THE 21 st CENTURY

CALIFORNIA S BIOTECHNOLOGY WORKFORCE TRAINING NEEDS FOR THE 21 st CENTURY CALIFORNIA S BIOTECHNOLOGY WORKFORCE TRAINING NEEDS FOR THE 21 st CENTURY Executive Summary Prepared for Applied Biological Technologies Initiative Economic and Workforce Development Program California

More information

Innovative Medicines Initiative (IMI) Future funding opportunities. Catherine Brett, IMI Conferencia H2020 y Salud Madrid, Spain 8 November 2017

Innovative Medicines Initiative (IMI) Future funding opportunities. Catherine Brett, IMI Conferencia H2020 y Salud Madrid, Spain 8 November 2017 Innovative Medicines Initiative (IMI) Future funding opportunities Catherine Brett, IMI Conferencia H2020 y Salud Madrid, Spain 8 November 2017 Outline What is IMI and why do we need it? How does IMI work?

More information

Commercialising early stage agbiotechnology from academia: challenges and opportunities. Rupert Osborn CEO, IP Pragmatics Ltd March 2011

Commercialising early stage agbiotechnology from academia: challenges and opportunities. Rupert Osborn CEO, IP Pragmatics Ltd March 2011 Commercialising early stage agbiotechnology from academia: challenges and opportunities Rupert Osborn CEO, IP Pragmatics Ltd March 2011 Overview Introduction to IP Pragmatics Agbiotechnology crop market

More information

The role of patients in clinical research

The role of patients in clinical research Biopeople Newsletter April: The role of patients in clinical research Pitch your life sc...page 1 of 10 Biopeople Newsletter April 2018 The role of patients in clinical research What is the place of patients

More information

A GATEWAY TO ACADEMIC EXCELLENCE FOR BIOTECH AND PHARMA

A GATEWAY TO ACADEMIC EXCELLENCE FOR BIOTECH AND PHARMA A GATEWAY TO ACADEMIC EXCELLENCE FOR BIOTECH AND PHARMA Découpe 6 8 12 Connecting meaningful endpoints: Ksilink s comprehensive translational effort Ksilink s Patient centered, translational technology

More information

GRI Sustainability Reporting Statistics Publication year By Report Services

GRI Sustainability Reporting Statistics Publication year By Report Services GRI Sustainability Reporting Statistics Publication year 2010 By Report Services GRI reports 1999-2010 2000 1800 1600 1400 1200 1000 800 600 400 200 0 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008

More information

Conference Exhibitors

Conference Exhibitors Conference Exhibitors CSM Executive and the 2018 Manitoba Local Organizing Committee would like to thank the following organizations for exhibiting and supporting the Canadian Society of Microbiologists

More information

Promotion and Sponsoring Options 2018

Promotion and Sponsoring Options 2018 05/14 2018 Make use of the well known and widely acknowledged Bio M network to promote your event, company and competencies! Bio M serves as the central hub and catalyst between academic research, pharmaceutical

More information

Director Healthcare Biotech

Director Healthcare Biotech Director Healthcare Biotech EuropaBio, the European Association for Bioindustries, promotes an innovative and dynamic European biotechnology industry. EuropaBio and its members are committed to the socially

More information

De la Investigación al Mercado Farmacéutico: Mecanismos de actuación y elementos tractores

De la Investigación al Mercado Farmacéutico: Mecanismos de actuación y elementos tractores De la Investigación al Mercado Farmacéutico: Mecanismos de actuación y elementos tractores Raúl Martín-Ruiz, PhD Sevilla, September 26 2018 Contents 01 From Academic Science to Product 02 What do we have

More information

So many science careers: find your own niche

So many science careers: find your own niche So many science careers: find your own niche Kristin Breitschopf sanofi-aventis Deutschland GmbH PhD degree and what next? Scientists have a wide range of career options Huge diversity of career opportunities

More information

A unique Collaborative Model for the Discovery of New Therapeutic Approaches

A unique Collaborative Model for the Discovery of New Therapeutic Approaches A unique Collaborative Model for the Discovery of New Therapeutic Approaches THE INNOVATION GAP OPEN INNOVATION TO ADDRESS THE LACK OF PRODUCTIVITY OF BIOPHARMACEUTICAL RESEARCH A PRE-COMPETITIVE PHARMA

More information

Clinical Trials: Facts and Trends. Dr Nik Nikitin. Founder/Director, Russlan Clinical. ManxBioMed Annual Bio Business Conference 10 th December 2013

Clinical Trials: Facts and Trends. Dr Nik Nikitin. Founder/Director, Russlan Clinical. ManxBioMed Annual Bio Business Conference 10 th December 2013 Clinical Trials: Facts and Trends Dr Nik Nikitin Founder/Director, Russlan Clinical What is a clinical trial? A clinical trial is a research study in human volunteers to answer specific health questions

More information

INSTITUT PASTEUR INSTITUT PASTEUR IS A PRIVATE, NON PROFIT, INSTITUTE DEDICATED TO RESEARCH & PUBLIC HEALTH

INSTITUT PASTEUR INSTITUT PASTEUR IS A PRIVATE, NON PROFIT, INSTITUTE DEDICATED TO RESEARCH & PUBLIC HEALTH www.pasteur.fr INSTITUT PASTEUR INSTITUT PASTEUR IS A PRIVATE, NON PROFIT, INSTITUTE DEDICATED TO RESEARCH & PUBLIC HEALTH INSTITUT PASTEUR Created in 1887 by Louis Pasteur 2,700 people working in Paris

More information

Hybrid Operating Room Market Research Report - Global Forecast Till 2023

Hybrid Operating Room Market Research Report - Global Forecast Till 2023 Report Information More information from: https://www.marketresearchfuture.com/reports/862 Hybrid Operating Room Market Research Report - Global Forecast Till 2023 Report / Search Code: MRFR/HC/0360-HCRR

More information

Current Topics of Pharmaceutical Regulatory Affairs in Japan

Current Topics of Pharmaceutical Regulatory Affairs in Japan Pharmaceuticals and Medical Devices Agency Current Topics of Pharmaceutical Regulatory Affairs in Japan Takeyuki SATO Associate Director (International and Product Evaluation Affairs), Centre for Product

More information

International Conference on Pharmacy and Pharmaceutical Sciences April 09-11, 2018, Dubai UAE

International Conference on Pharmacy and Pharmaceutical Sciences April 09-11, 2018, Dubai UAE International Conference on Pharmacy and Pharmaceutical Sciences April 09-11, 2018, Dubai UAE EMAIL: pharmacy@citationsinternational.com VISIT OUR WEBSITE: https://www.citationsinternational.com/pharmacy-conference-2018#about

More information

Biotechnology industry: future needs and trends. Roland Wohlgemuth

Biotechnology industry: future needs and trends. Roland Wohlgemuth Biotechnology industry: future needs and trends Roland Wohlgemuth Overview Introduction Innovation Outlook and Opportunities Introduction European Federation of Biotechnology (EFB) http://www.efb-central.org

More information

ETB funding initiative: Transnational R&D&I Cooperation of Biotech SMEs

ETB funding initiative: Transnational R&D&I Cooperation of Biotech SMEs ETB funding initiative: Transnational R&D&I Cooperation of Biotech SMEs www.eurotransbio.eu What is EuroTransBio? EuroTransBio (ETB) is an international funding initiative of European program owners and

More information

J.P. MORGAN Healthcare Conference Robert Friel Chairman and CEO January 10, 2018

J.P. MORGAN Healthcare Conference Robert Friel Chairman and CEO January 10, 2018 J.P. MORGAN Healthcare Conference Robert Friel Chairman and CEO January 10, 2018 Factors affecting future performance & non-gaap financial measures This presentation contains "forward-looking" statements

More information

Nanomedicine Translation Hub and EU-NCL: Custom mentoring, product characterization and GMP manufacturing of Med-NPs

Nanomedicine Translation Hub and EU-NCL: Custom mentoring, product characterization and GMP manufacturing of Med-NPs Nanomedicine Translation Hub and EU-NCL: Custom mentoring, product characterization and GMP manufacturing of Med-NPs Fanny Caputo, CEA Grenoble fanny.caputo@cea.fr Index Presentation of the European Technology

More information

- OMICS IN PERSONALISED MEDICINE

- OMICS IN PERSONALISED MEDICINE SUMMARY REPORT - OMICS IN PERSONALISED MEDICINE Workshop to explore the role of -omics in the development of personalised medicine European Commission, DG Research - Brussels, 29-30 April 2010 Page 2 Summary

More information

Commerzbank German Investment Seminar 2012

Commerzbank German Investment Seminar 2012 Commerzbank German Investment Seminar 2012 Matthias Zachert Chief Financial Officer New York, January 11, 2012 Agenda 1 The Merck Group 2 Key strengths 3 Unlocking value 4 Financials 5 Summary 2 Merck

More information

Brazilian Policies and Programs in BIOECONOMY

Brazilian Policies and Programs in BIOECONOMY Brazilian Policies and Programs in BIOECONOMY Bruno Nunes CGBE/SEPED/MCTIC São Paulo, November 8 th, 2017 GLOBAL CHALLENGES CLIMATE CHANGES AND GLOBAL WARMING DEMOGRAPHIC CHANGES Population growth Increase

More information

Cheuvreux German Corporate Conference 2012

Cheuvreux German Corporate Conference 2012 Cheuvreux German Corporate Conference 2012 Matthias Zachert Chief Financial Officer Frankfurt, January 17, 2012 Agenda 1 The Merck Group 2 Key strengths 3 Unlocking value 4 Financials 5 Summary 2 Merck

More information

UNLEASH THE POWER OF PRECISION MEDICINE

UNLEASH THE POWER OF PRECISION MEDICINE FROM BENCH TO BEDSIDE UNLEASH THE POWER OF PRECISION MEDICINE DCB, pioneer in biotech. Your partner in drug discovery. www.dcb.org.tw The Center for Biotechnology With over 400 dedicated researchers and

More information

Konica Minolta to Acquire Invicro (US)

Konica Minolta to Acquire Invicro (US) Konica Minolta to Acquire Invicro (US) Acceleration of expansion of precision medicine business Offering new value for drug discovery and development in immuno-oncology and neurodegenerative disease September

More information

Rare diseases in the 7th EU Framework Programme for Research and Technological Development

Rare diseases in the 7th EU Framework Programme for Research and Technological Development Rare diseases in the 7th EU Framework Programme for Research and Technological Development Manuel Hallen, MD Head of Unit Medical & Public Health Research DG Research European Commission 1 The role of

More information

State of Washington s Life Sciences Sector. Chris E. Rivera President, WBBA

State of Washington s Life Sciences Sector. Chris E. Rivera President, WBBA State of Washington s Life Sciences Sector Chris E. Rivera President, WBBA Washington Biotechnology and Biomedical Association (WBBA) Who we are A not-for-profit association of > 460 life science companies,

More information

[ Feature ] Biotechnology Parks: China into the Next Future

[ Feature ] Biotechnology Parks: China into the Next Future Photo credit: China Beijing Bioengineering and Pharmaceutical Industrial Park (CBP) More than just an incubator base for research and discovery, China Beijing Bioengineering and Pharmaceutical Industrial

More information

1.0 Background to the organisation

1.0 Background to the organisation 1.0 Background to the organisation The National University of Ireland Galway, the Royal College of Surgeons in Ireland, University College Cork, University College Dublin and Trinity College and their

More information

EY Life Sciences. Key themes from The Next Frontiers in Precision Medicine panel. February 2016

EY Life Sciences. Key themes from The Next Frontiers in Precision Medicine panel. February 2016 EY Life Sciences Key themes from The Next Frontiers in Precision Medicine panel February 2016 Evolution of precision medicine One-size-fits-all therapeutics Precision medicine Disconnected health care

More information

Utrecht Region. A key role in the Netherlands pharma/ biotech industries. Why locate your pharma/ biotech company in the Utrecht Region?

Utrecht Region. A key role in the Netherlands pharma/ biotech industries. Why locate your pharma/ biotech company in the Utrecht Region? Utrecht Region A key role in the Netherlands pharma/ biotech industries Why locate your pharma/ biotech company in the Utrecht Region? The pharmaceutical and biotech sectors in the region s life sciences

More information

ITALIAN HI-TECH INDUSTRY: THE CASE OF LIFE SCIENCES

ITALIAN HI-TECH INDUSTRY: THE CASE OF LIFE SCIENCES ITALIAN HI-TECH INDUSTRY: THE CASE OF LIFE SCIENCES Part Two Executive summary National Interest January 2015 Study conducted by the IMT Institute for Advanced Studies Lucca, the Fondazione CERM, AIFA,

More information

A gateway to academic excellence for Biotech and Pharma

A gateway to academic excellence for Biotech and Pharma A gateway to academic excellence for Biotech and Pharma 6 8 12 Connecting meaningful endpoints: Ksilink s comprehensive translational effort Ksilink s patient centered, translational technology Engaging

More information